1/23/2019 4:23:33 PM
Kadmon Appoints Cynthia Schwalm To Board Of Director
1/4/2019 4:27:23 PM
Kadmon Appoints Tasos Konidaris As Interim Chairman
12/3/2018 10:08:56 AM
Kadmon Announces Updated Findings From Ongoing Phase 2 Clinical Trial Of KD025 In CGVHD
11/29/2018 9:16:24 AM
Kadmon Holdings Presents Data On New ROCK Inhibitor Clinical Candidate At Anti-Fibrotic Drug Development Summit
11/9/2018 4:48:37 PM
Kadmon Holdings Q3 Loss Per Share $0.13 Vs. $0.42 Last Year
10/17/2018 9:04:22 AM
FDA Grants Breakthrough Therapy Designation To Kadmon's KD025 For Chronic Graft-Versus-Host Disease
10/17/2018 8:07:22 AM
WBB Securities Upgrades Kadmon Holdings LLC (KDMN) To Hold From Sell With $2.90 Price Target
6/11/2018 8:45:31 PM
Kadmon Holdings Prices Offering Of 30.30 Mln Shares At $3.30/shr
4/10/2018 8:05:57 AM
Kadmon Receives Final Minutes From A March 2018 Type C Meeting With FDA Regarding Development Pathway For KD025
2/12/2018 4:08:47 PM
Kadmon Reports Positive Topline Results From Phase 2 Study Of KD025 In Idiopathic Pulmonary Fibrosis
10/9/2017 9:35:13 AM
WBB Securities Cuts Kadmon Holdings LLC (KDMN) To Sell From Hold With $3 Price Target
3/16/2017 8:54:19 AM
WBB Securities Raises Kadmon Holdings LLC (KDMN) To Hold From Sell With $3.25 Price Target
8/1/2016 9:54:05 AM
WBB Securities Starts Kadmon Holdings LLC (KDMN) At Sell With $7.50 Price Target